Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The SWI/SNF complex in cancer — biology, biomarkers and therapy
Priya Mittal, Charles W.M. Roberts
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 435-448
Open Access | Times Cited: 472

Showing 1-25 of 472 citing articles:

Biomolecular Condensates and Cancer
Ann Boija, Isaac A. Klein, Richard A. Young
Cancer Cell (2021) Vol. 39, Iss. 2, pp. 174-192
Open Access | Times Cited: 238
Hepatocellular carcinoma: old friends and new tricks
Eunsun Kim, Patrick Viatour
Experimental & Molecular Medicine (2020) Vol. 52, Iss. 12, pp. 1898-1907
Open Access | Times Cited: 236
Acute BAF perturbation causes immediate changes in chromatin accessibility
Sandra Schick, Sarah Grosche, Katharina Eva Kohl, et al.
Nature Genetics (2021) Vol. 53, Iss. 3, pp. 269-278
Open Access | Times Cited: 142
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Molecular events in neuroendocrine prostate cancer development
Yong Wang, Yu Wang, Xinpei Ci, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 10, pp. 581-596
Open Access | Times Cited: 122
cBAF complex components and MYC cooperate early in CD8+ T cell fate
Ao Guo, Hongling Huang, Zhexin Zhu, et al.
Nature (2022) Vol. 607, Iss. 7917, pp. 135-141
Open Access | Times Cited: 117
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer
Shenghong Ma, Tracy Tang, Gary D. Probst, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential
Xuemeng Xu, Peng Qiu, Xianjie Jiang, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1357-1370
Open Access | Times Cited: 96
Structure of human chromatin-remodelling PBAF complex bound to a nucleosome
Junjie Yuan, Kangjing Chen, Wenbo Zhang, et al.
Nature (2022) Vol. 605, Iss. 7908, pp. 166-171
Closed Access | Times Cited: 82
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 79
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer
Hanling Wang, Ni Li, Qiuli Liu, et al.
Cancer Cell (2023) Vol. 41, Iss. 7, pp. 1345-1362.e9
Closed Access | Times Cited: 74
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Fernando J. de Miguel, Claudia Gentile, William W. Feng, et al.
Cancer Cell (2023) Vol. 41, Iss. 8, pp. 1516-1534.e9
Open Access | Times Cited: 53
Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion
Elena Battistello, Kimberlee A. Hixon, Dawn E. Comstock, et al.
Molecular Cell (2023) Vol. 83, Iss. 8, pp. 1216-1236.e12
Open Access | Times Cited: 44
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Matthew B. Maxwell, Marianne S. Hom, Jawoon Yi, et al.
Cell (2024) Vol. 187, Iss. 13, pp. 3390-3408.e19
Closed Access | Times Cited: 33
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Brian Ortmann
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000154-e000154
Open Access | Times Cited: 23
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A. Myers, et al.
Nature (2024) Vol. 628, Iss. 8007, pp. 442-449
Closed Access | Times Cited: 20
Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 20
The Role of SWI/SNF Complex in Bladder Cancer
Zhenlain Lei, Yanfeng Han, John B. Liao, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
Rishi G. Vaswani, David S. Huang, Neville J. Anthony, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
SMARCA2 protein: structure, function and perspectives of drug design
Zhaolin Guo, Peng Wang, Yuxuan Han, et al.
European Journal of Medicinal Chemistry (2025), pp. 117319-117319
Closed Access | Times Cited: 2
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V. Alessi, Biagio Ricciuti, Liam F. Spurr, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 7, pp. 1176-1187
Closed Access | Times Cited: 96
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Maite G. Fernández‐Barrena, María Arechederra, Leticia Colyn, et al.
JHEP Reports (2020) Vol. 2, Iss. 6, pp. 100167-100167
Open Access | Times Cited: 94
Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes
Bennett Wolf, Yanding Zhao, Andrew McCray, et al.
Nature Structural & Molecular Biology (2022) Vol. 30, Iss. 1, pp. 10-21
Open Access | Times Cited: 68
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Shouying Xu, Chao Tang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 67
BRAF mutations in thyroid cancer
Rafael Selbach Scheffel, José Miguel Dora, Ana Luiza Maia
Current Opinion in Oncology (2021) Vol. 34, Iss. 1, pp. 9-18
Closed Access | Times Cited: 60
Page 1 - Next Page

Scroll to top